Protalix BioTherapeutics (PLX) 10-K2013 FY Annual report

Filed: 13 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AAT, accessible, actin, Agencia, al, alia, alleviated, Allianz, alpha, anti, biobetter, Biozone, British, Budgetary, capsule, Chile, Codification, ConA, concanavalin, conversion, corroborated, counterparty, Crohn, Cruz, customer, cystic, daily, de, default, deoxyribonuclease, DNase, downstream, El, ELELYSOTM, Eliglustat, embedded, evidenced, extracellular, Fiocruz, fromselling, gamma, gazette, GenzymeCorporation, hierarchy, housekeeping, indenture, inflammatory, inhalation, inhibitor, inter, interferon, intravenously, Korea, Latin, LDN, lysosomalstorage, mature, maturity, max, mediated, Mellon, merged, Mexican, Mine, Nacional, Network, obsolescence, Ocure, OphthaliX, orderly, Oswaldo, ourSupply, payroll, Pharma, placement, polypeptide, prematurely, Pulmozyme, recovered, redeem, redeemed, refinance, remitted, repurchase, Reshumot, SAE, Samara, Sanitaria, segment, semiannually, shipping, Siklu, sinking, steady, surrendered, Surveillance, Symposium, Telecom, tenure, theUnited, thick, thrombocytopenic, title, unadjusted, unobservable, unpaid, Unresolved, UPLYSO, UPLYSOin, UPLYSON, UPLYSOTM, UPLYSOTMin, Velox, Vigilancia, vulnerability, worth, YP

Removed: acetylcholinesterase, AChE, Alfred, ALRO, Amending, analogue, Ashkelon, begin, Bio, biochemical, biodefense, Biomed, Biomedix, Boyce, breaching, Chlorogen, Communication, consummated, Contipi, Cornell, COSO, deliverable, diligence, ecocycle, EMD, Endocrinology, Entera, Entrepreneurship, entry, extending, founder, gas, gefen, gradually, incidence, incremental, Incubator, insolvency, Ithaca, Lauterbach, Lecturer, liquidator, live, lowered, Misgav, MOFET, multinational, nerve, pesticide, plc, proceeding, prophylactic, recapitalization, receiver, reconstructive, repeated, resolution, reversed, revert, rodent, Sandra, Serono, soluble, spend, stipulating, sublicensing, SUPPLEMENTARY, surface, survive, survived, Thompson, toxicity, TransBiodiesel, undisclosed, untoward, validity, Vigilance, Yissum

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PLX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

PROTALIX BIOTHERAPEUTICS, INC.

CERTIFICATION

In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Dated: March 13, 2014

/s/ David Aviezer

David Aviezer, Ph.D.

President and Chief Executive Officer